Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash & Equivalents (2019 - 2025)

Volitionrx (VNRX) has disclosed Cash & Equivalents for 8 consecutive years, with $199407.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 96.32% year-over-year to $199407.0, compared with a TTM value of $199407.0 through Sep 2025, down 96.32%, and an annual FY2024 reading of $3.3 million, down 84.25% over the prior year.
  • Cash & Equivalents was $199407.0 for Q3 2025 at Volitionrx, down from $2.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $33.1 million in Q1 2021 and bottomed at $199407.0 in Q3 2025.
  • Average Cash & Equivalents over 5 years is $13.2 million, with a median of $10.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 559.07% in 2023, then plummeted 96.32% in 2025.
  • Year by year, Cash & Equivalents stood at $20.6 million in 2021, then tumbled by 47.2% to $10.9 million in 2022, then skyrocketed by 90.76% to $20.7 million in 2023, then tumbled by 84.25% to $3.3 million in 2024, then crashed by 93.89% to $199407.0 in 2025.
  • Business Quant data shows Cash & Equivalents for VNRX at $199407.0 in Q3 2025, $2.3 million in Q2 2025, and $2.6 million in Q1 2025.